리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 10월
페이지 정보:영문 133 Pages
라이선스 & 가격 (부가세 별도)
한글목차
해양 의약품 세계 시장은 2030년까지 69억 달러에 달할 것으로 전망
2023년 41억 달러로 추정되는 해양 의약품 세계 시장은 2023-2030년 분석 기간 동안 연평균 7.6% 성장하여 2030년에는 69억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 종양학 최종 용도 부문은 CAGR 8.1%를 기록하여 분석 기간 종료 시점에 33억 달러에 도달할 것으로 예상됩니다. 심혈관계 최종 용도 분야의 성장률은 분석 기간 동안 CAGR 7.5%로 추정됩니다.
미국 시장 11억 달러로 추정, 중국은 CAGR 7.3%로 성장 전망
미국의 해양 의약품 시장은 2023년 11억 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 11억 달러의 시장 규모에 도달할 것으로 예상되며, 2023-2030년 분석 기간 동안 7.3%의 CAGR을 기록할 것으로 예측됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 7.0%와 6.4%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 약 6.0%의 CAGR로 성장할 것으로 예상됩니다.
세계 해양의약품 시장 - 주요 동향 및 촉진요인 정리
해양 의약품이란 무엇이며, 현대 의학에서 왜 중요한가?
해양 의약품은 해조류, 해면동물, 연체동물, 박테리아 등 해양 생물에서 추출한 의약품 및 치료 화합물을 말합니다. 이들 화합물은 독특한 화학 구조와 생물학적 활성을 가지고 있어 암, 염증, 감염 등 다양한 질병을 치료하는 데 유용합니다. 해양 환경, 특히 심해 분출구와 산호초와 같은 극한 환경은 새로운 약물 후보로 잠재력을 지닌 생물 활성 물질의 보고입니다. 연구 개발자와 제약사들은 보다 효과적인 새로운 치료법을 찾기 위해 해양 생물에 함유된 천연 화합물을 활용하여 독특한 작용 기전을 가진 약물을 개발하기 위해 해양 생물 다양성을 점점 더 많이 탐색하고 있습니다. 대표적인 예로는 만성 통증 관리에 사용되는 디코노타이드와 항암제 트라벡테딘과 같은 해양 유래 의약품을 들 수 있습니다. 해양 자원에서 신약을 발견할 수 있는 가능성은 생명공학 및 제약 산업에서 해양 의약품을 유망하고 빠르게 발전할 수 있는 분야로 자리매김하고 있습니다.
기술의 발전은 해양 신약 개발의 가능성을 어떻게 넓히고 있는가?
기술의 발전은 해양 의약품의 발견과 개발의 가능성을 크게 넓혀주었습니다. 유전체학, 단백질체학, 대사체학 등 최신 기술을 통해 과학자들은 분자 수준에서 해양 생물 다양성을 탐색하고 생물학적 활성 화합물을 보다 효율적으로 식별하고 분리할 수 있게 되었습니다. 또한, 심해 탐사 기술과 원격조종로봇(ROV)의 개발로 연구자들은 이전에는 접근할 수 없었던 해양 환경에 접근할 수 있게 되어 독특한 생화학적 특성을 가진 새로운 생물체를 발견할 수 있는 가능성이 높아졌습니다. 또한, 고처리 스크리닝과 바이오 프로스펙팅의 발전으로 해양 생물에서 신약 후보물질의 발굴이 가속화되고 있습니다. 또한, 합성생물학 및 생물공학의 혁신은 제약회사들이 실험실에서 해양 화합물을 재현하여 천연 해양 자원을 고갈시키지 않고도 지속가능한 생산을 보장할 수 있도록 돕고 있습니다. 이러한 기술의 비약적인 발전은 해양 의약품 개발의 진보를 촉진하고 기존 치료법에 내성을 보이는 질병에 대한 새로운 치료법의 문을 열어주고 있습니다.
지속가능성과 규제가 해양 의약품의 성장에 필수적인 이유는 무엇인가?
의약품 개발을 위한 해양 환경 탐사는 지속가능성과 규제에 대한 중요한 고려사항을 제기합니다. 의약품 개발을 위한 해양생물 채취는 특히 산호초나 심해 환경과 같은 취약한 생태계에서 생태계에 큰 영향을 미칠 수 있습니다. 이에 따라 제약회사와 연구자들은 양식, 합성 생산, 미생물 발효를 통한 해양 화합물 조달 등 지속가능한 방법을 채택해야 한다는 압력이 커지고 있습니다. 또한, 해양 생물 시료에 대한 규제가 진화하고 있으며, 각국은 영해 내 해양 자원 채취를 더욱 엄격하게 규제하고 있습니다. 유전자원에 대한 접근을 규정하는 나고야 의정서와 같은 국제 협약은 해양 의약품 탐사를 둘러싼 정책을 형성하는 데 중요한 역할을 하고 있습니다. 기업들은 환경에 미치는 영향을 최소화하면서 윤리적이고 합법적으로 해양 화합물을 획득하기 위해 이러한 규제 프레임워크를 잘 활용해야 합니다.
해양 의약품 세계 시장 성장의 원동력은?
세계 해양 의약품 시장의 성장은 해양 생명공학 기술의 발전, 연구 자금의 증가, 질병 퇴치를 위한 신약에 대한 수요 증가 등 여러 가지 요인에 의해 주도되고 있습니다. 특히 새로운 항생제 및 항암제 탐색에 있어 해양이 생물학적 활성 화합물의 미개발 원천이라는 인식이 높아진 것이 주요 성장 요인 중 하나입니다. 하이스루풋 스크리닝과 바이오인포매틱스와 같은 신약개발 기술의 발전으로 해양 생물에서 잠재적인 약물 후보를 쉽게 찾아낼 수 있게 되었습니다. 또한, 약제 내성 질환의 증가와 대체 요법의 필요성도 해양 유래 의약품에 대한 관심을 높이고 있습니다. 또한, 학계, 연구기관, 제약회사 간의 공동연구가 확대되면서 이 분야의 기술 혁신이 가속화되고 있습니다. 정부 및 민간단체는 해양 신약개발 프로그램에 대한 투자를 늘리고 있으며, 이는 시장 성장을 더욱 촉진하고 있습니다. 해양 생물 다양성의 잠재력에 대한 인식이 높아짐에 따라 해양 의약품 시장은 지속적으로 확대될 것으로 예상됩니다.
조사 대상 기업 예시(주목받는 43개 기업)
AbbVie, Inc.
Aphios Corporation
BioMarin Pharmaceutical
Cyanotech Corporation
GlycoMar Ltd.
GSK Plc
MARINE LIFESCIENCES
Marine Polymer Technologies, Inc.
Marinomed Biotech AG
Pelagia AS
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 성장 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
ksm
영문 목차
영문목차
Global Marine Pharmaceuticals Market to Reach US$6.9 Billion by 2030
The global market for Marine Pharmaceuticals estimated at US$4.1 Billion in the year 2023, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Oncology End-Use, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Cardiovascular End-Use segment is estimated at 7.5% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.3% CAGR
The Marine Pharmaceuticals market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.
Global Marine Pharmaceuticals Market - Key Trends & Drivers Summarized
What Are Marine Pharmaceuticals, and Why Are They Important in Modern Medicine?
Marine pharmaceuticals refer to drugs and therapeutic compounds derived from marine organisms such as algae, sponges, mollusks, and bacteria. These compounds have unique chemical structures and biological activities that make them valuable for treating a wide range of diseases, including cancer, inflammation, and infectious diseases. Marine environments, particularly extreme habitats like deep-sea vents and coral reefs, have become a treasure trove of bioactive substances that offer potential as novel drug candidates. Researchers and pharmaceutical companies are increasingly exploring the ocean's biodiversity for new, more effective treatments, leveraging the natural compounds found in marine organisms to develop drugs with unique mechanisms of action. Some notable examples include marine-derived drugs like ziconotide, used for chronic pain management, and trabectedin, an anti-cancer agent. The potential for discovering novel drugs from marine resources has positioned marine pharmaceuticals as a promising and rapidly evolving field within the biotechnology and pharmaceutical industries.
How Are Technological Advancements Expanding Opportunities in Marine Drug Discovery?
Technological advancements have significantly expanded the possibilities for discovering and developing marine pharmaceuticals. Modern techniques like genomics, proteomics, and metabolomics allow scientists to explore marine biodiversity at a molecular level, identifying and isolating bioactive compounds more efficiently. The development of deep-sea exploration technology and remote-operated vehicles (ROVs) has also enabled researchers to access previously unreachable marine environments, increasing the potential for finding new organisms with unique biochemical properties. Furthermore, advancements in high-throughput screening and bioprospecting have accelerated the identification of drug candidates from marine organisms. Innovations in synthetic biology and bioengineering are also helping pharmaceutical companies recreate marine compounds in the laboratory, ensuring sustainable production without depleting natural marine resources. These technological breakthroughs are driving progress in marine drug development, opening the door to new treatments for diseases that are resistant to traditional therapies.
Why Are Sustainability and Regulation Crucial to the Growth of Marine Pharmaceuticals?
The exploration of marine environments for pharmaceutical development raises important sustainability and regulatory considerations. Harvesting marine organisms for drug development can have significant ecological impacts, particularly in fragile ecosystems such as coral reefs or deep-sea environments. As a result, there is increasing pressure on pharmaceutical companies and researchers to adopt sustainable practices, such as sourcing marine compounds through aquaculture, synthetic production, or microbial fermentation. Additionally, the regulation of marine bioprospecting is evolving, with countries enforcing stricter controls on the extraction of marine resources within their territorial waters. International agreements like the Nagoya Protocol, which governs access to genetic resources, are playing a key role in shaping the policies around marine pharmaceutical exploration. Companies must navigate these regulatory frameworks to ensure the ethical and legal acquisition of marine compounds while minimizing their environmental footprint.
What Is Driving the Growth of the Global Marine Pharmaceuticals Market?
The growth in the global marine pharmaceuticals market is driven by several factors, including advances in marine biotechnology, increased research funding, and the rising demand for novel drugs to combat diseases. One key growth driver is the growing recognition of the ocean as an untapped source of biologically active compounds, particularly in the search for new antibiotics and anti-cancer agents. Technological advancements in drug discovery, such as high-throughput screening and bioinformatics, are making it easier to identify potential drug candidates from marine organisms. The increasing prevalence of drug-resistant diseases and the need for alternative therapies are also fueling interest in marine-derived pharmaceuticals. Furthermore, the expansion of collaborative efforts between academic institutions, research organizations, and pharmaceutical companies is accelerating innovation in the field. Governments and private entities are increasing investments in marine drug discovery programs, further driving market growth. As awareness of marine biodiversity’s potential grows, the marine pharmaceuticals market is poised for continued expansion.
Select Competitors (Total 43 Featured) -
AbbVie, Inc.
Aphios Corporation
BioMarin Pharmaceutical
Cyanotech Corporation
GlycoMar Ltd.
GSK Plc
MARINE LIFESCIENCES
Marine Polymer Technologies, Inc.
Marinomed Biotech AG
Pelagia AS
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Marine Pharmaceuticals - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Focus on Drug Discovery from Marine Sources Throws Spotlight on the Growing Potential of Marine Pharmaceuticals
Rising Prevalence of Drug-Resistant Diseases Spurs Significant Growth in Research for Marine-Derived Antibiotics
Technological Advancements in Marine Biotechnology Strengthens the Business Case for Exploring Novel Marine Bioactive Compounds
Expansion of Marine Bioprospecting Expands Addressable Market Opportunity for Marine-Based Drug Development
Rising Demand for Alternative Cancer Treatments Drives Adoption of Marine-Derived Anticancer Compounds
Growing Awareness of Sustainability and Eco-Friendly Sourcing Generates Demand for Sustainable Harvesting of Marine Pharmaceuticals
Increasing Use of Marine-Derived Compounds in Chronic Disease Management Propels Growth in Marine Pharmaceuticals
Integration of Genomics and Bioinformatics in Marine Drug Discovery Strengthens the Case for More Targeted Drug Development
Rising Investment in Marine Biotechnology Research Generates Opportunities for New Therapeutic Agents from Marine Organisms
Increased Focus on Marine Ecosystem Conservation Expands the Need for Sustainable Marine Pharmaceutical Practices
Growing Demand for Natural and Biocompatible Therapies Propels Market Growth for Marine-Derived Nutraceuticals and Pharmaceuticals
Advancements in Extraction and Cultivation Techniques Drive Adoption of Marine Pharmaceuticals by Reducing Production Costs
Rising Incidence of Neurological Disorders Expands Research into Marine-Derived Neuroprotective Agents
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Marine Pharmaceuticals Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Marine Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Marine Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Marine Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Oncology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Oncology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Oncology End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Cardiovascular End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Cardiovascular End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Infectious Diseases End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Infectious Diseases End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Infectious Diseases End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
TABLE 20: Canada Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Canada Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Canada 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 23: Japan Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Japan Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Japan 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 26: China Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: China Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: China 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 29: Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Marine Pharmaceuticals by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Marine Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 32: Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 35: France Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: France Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: France 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 38: Germany Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Germany Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Germany 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
TABLE 41: Italy Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Italy Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Italy 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 44: UK Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: UK Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: UK 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Rest of Europe Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Rest of Europe 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Asia-Pacific Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Asia-Pacific 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 53: Rest of World Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Rest of World Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Rest of World 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030